RAPT Therapeutics (NASDAQ:RAPT) Trading Up 10.3% After Analyst Upgrade

RAPT Therapeutics (NASDAQ:RAPT)’s share price was up 10.3% during mid-day trading on Wednesday after UBS Group raised their price target on the stock from $26.00 to $31.00. UBS Group currently has a buy rating on the stock. RAPT Therapeutics traded as high as $31.46 and last traded at $27.53, approximately 205,100 shares changed hands during mid-day trading. An increase of 95% from the average daily volume of 105,237 shares. The stock had previously closed at $24.95.

A number of other brokerages have also recently weighed in on RAPT. Wells Fargo & Co started coverage on shares of RAPT Therapeutics in a research note on Monday, November 25th. They set an “outperform” rating and a $33.00 price target for the company. BMO Capital Markets started coverage on shares of RAPT Therapeutics in a research note on Monday, November 25th. They set an “outperform” rating and a $35.00 price target for the company.

In other news, major shareholder Group Ii Lp Column acquired 625,000 shares of the business’s stock in a transaction on Monday, November 4th. The stock was bought at an average price of $14.49 per share, for a total transaction of $9,056,250.00. Also, CEO Brian Russell Wong acquired 25,000 shares of the business’s stock in a transaction on Monday, November 4th. The shares were purchased at an average price of $14.49 per share, with a total value of $362,250.00. In the last quarter, insiders have purchased 651,600 shares of company stock valued at $9,441,684.

RAPT Therapeutics Company Profile (NASDAQ:RAPT)

RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.

See Also: Municipal Bonds

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.